NASDAQ · MDCX

Medicus Pharma Ltd.

$0.32 -$0.05 (-14.00%) 1D After hours

Key Metrics

$20.96M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 1.02
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 5
    From its Feb 27 high, the share price fell 82%.

    Peak close $1.53 on Feb 27; trough close $0.28 on May 5. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -82%
  • Mar 6
    The stock moved -42.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 6
  • Mar 5
    The stock moved -50.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$20.96M
Enterprise value
Shares outstanding56.7M
52-wk range$0.25 – $3.05
Avg volume · 20D1.4M
Net cash
Book value / share
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Medicus Pharma Ltd.
IPO dateNov 22, 2023
Employees16

Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value